Patents by Inventor Michael Hayden

Michael Hayden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF PRIDOPIDINE FOR TREATING RETT SYNDROME
    Publication number: 20230165849
    Abstract: The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject.
    Type: Application
    Filed: November 19, 2020
    Publication date: June 1, 2023
    Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michal GEVA, Ralph LAUFER, Michael HAYDEN
  • USE OF PRIDOPIDINE FOR TREATING ANXIETY AND DEPRESSION
    Publication number: 20230112948
    Abstract: This invention provides a method of treating depression or anxiety in a human subject by administering a composition comprising pridopidine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 17, 2022
    Publication date: April 13, 2023
    Applicant: Prilenia Neurotherapeutics Ltd.
    Inventors: Michael HAYDEN, Michal GEVA
  • TREATMENT OF VIRAL INFECTION, DISEASE OR DISORDER USING A SELECTIVE S1R AGONIST
    Publication number: 20230100072
    Abstract: The subject invention provides a method for treating, reducing the incidence, suppressing or inhibiting a viral infection, disease, disorder or symptoms thereof in a subject in need thereof comprising administering to the subject a selective S1R agonist. In another aspect, the viral disease is COVID-19, and the selective S1R agonist is pridopidine or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 4, 2022
    Publication date: March 30, 2023
    Applicant: Prilenia Neurotherapeutics Ltd.
    Inventors: Michael HAYDEN, Michal GEVA
  • Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
    Patent number: 11471449
    Abstract: This invention provides a method of improving cognitive function in a subject comprising periodically administering to the subject an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to improve a cognitive function in the subject. The invention also provides a method of treating a subject afflicted with Alzheimer's disease, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to treat the subject.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: October 18, 2022
    Assignees: Prilenia Neurotherapeutics Ltd., The Board of Regents of the University of Texas System
    Inventors: Michal Geva, Ilya Bezprozvanny, Merav Bassan, Michael Hayden
  • Method of treating amyotrophic lateral sclerosis with pridopidine
    Patent number: 11406625
    Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine as monotherapy or together with riluzole, edaravone, combination of dextromethorphan/quinidine, sodium phenylbutyrate (PB), tauroursodeoxycholic acid or combination of sodium phenylbutyrate (PB)/tauroursodeoxycholic acid (i.e. AMX0035) as combination or add-on therapy.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: August 9, 2022
    Assignee: Prilenia Neurotherapeutics Ltd.
    Inventors: Michal Geva, Ralph Laufer, Michael Hayden, Neta Zach
  • USE OF PRIDOPIDINE FOR THE TREATMENT OF FRAGILE X SYNDROME
    Publication number: 20220202798
    Abstract: The invention provides a method of treating a subject afflicted with fragile X syndrome (FXS) or a FXS related disorder, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.
    Type: Application
    Filed: January 31, 2022
    Publication date: June 30, 2022
    Applicants: PRILENIA NEUROTHERAPEUTICS LTD., NATIONAL UNIVERSITY OF SINGAPORE, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Michael HAYDEN, Mahmoud Abdulhossein POULADI
  • LOW DOSE PRIDOPIDINE FOR PARKINSON'S DISEASE AND OTHER DISEASES ASSOCIATED WITH PARKINSONISM
    Publication number: 20220193059
    Abstract: The subject invention provides a method for treating Parkinsonism or symptoms thereof by low dose pridopidine.
    Type: Application
    Filed: February 4, 2020
    Publication date: June 23, 2022
    Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michael HAYDEN, Michal GEVA, Angela CENCI NILSSON
  • Use of pridopidine for the treatment of fragile X syndrome
    Patent number: 11234973
    Abstract: The invention provides a method of treating a subject afflicted with fragile X syndrome (FXS) or a FXS related disorder, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: February 1, 2022
    Assignees: PRILENIA NEUROTHERAPEUTICS LTD., NATIONAL UNIVERSITY OF SINGAPORE, Agency for Science, Technology and Research
    Inventors: Michael Hayden, Mahmoud Abdulhossein Pouladi
  • Use of pridopidine for treating functional decline
    Patent number: 11207310
    Abstract: This invention provides a method of maintaining functional capacity, improving functional capacity, or lessening the decline of functional capacity in a human patient comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine such that a dose of 90-225 mg of pridopidine is administered to the patient per day, so as to thereby maintain functional capacity, improve functional capacity, or lessen the decline of functional capacity in the human patient.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: December 28, 2021
    Assignee: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michael Hayden, Spyridon Papapetropoulos, Juha-Matti Savola, Eli Eyal, Beth Borowsky, Igor Grachev
  • PRIDOPIDINE FOR TREATING DRUG INDUCED DYSKINESIAS
    Publication number: 20210275512
    Abstract: The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine or pharmaceutically acceptable salt thereof effective to treat the subject.
    Type: Application
    Filed: May 10, 2021
    Publication date: September 9, 2021
    Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michal GEVA, Aric Orbach, Michael Hayden
  • PRIDOPIDINE FOR THE TREATMENT OF MITOCHONDRIAL-ASSOCIATED DISEASES AND DISORDERS AND ENDOPLASMIC RETICULUM (ER) STRESS
    Publication number: 20210220342
    Abstract: The subject invention provides a method for treating a subject afflicted with a disease, disorder, or condition associated with mitochondrial dysfunction or ER stress, comprising administering to the subject a composition comprising pridopidine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 23, 2021
    Publication date: July 22, 2021
    Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michael HAYDEN, Michal GEVA, Ana Cristina CARVALHO REGO
  • Pridopidine for treating drug induced dyskinesias
    Patent number: 11000519
    Abstract: The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia. The invention also provides pharmaceutical compositions suitable for carrying out these methods and packages containing such pharmaceutical compositions.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: May 11, 2021
    Assignee: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michal Geva, Aric Orbach, Michael Hayden
  • USE OF PRIDOPIDINE FOR THE TREATMENT OF ANXIETY AND DEPRESSION
    Publication number: 20210106572
    Abstract: The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject.
    Type: Application
    Filed: November 19, 2020
    Publication date: April 15, 2021
    Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michal GEVA, Ralph LAUFER, Michael HAYDEN
  • USE OF PRIDOPIDINE FOR THE TREATMENT OF ANXIETY AND DEPRESSION
    Publication number: 20210093622
    Abstract: The invention provides a method of reducing anxiety and/or depression in a subject comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to reduce anxiety and/or depression in a subject.
    Type: Application
    Filed: October 20, 2020
    Publication date: April 1, 2021
    Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michael HAYDEN, Mahmoud Abdulhossein POULADI
  • USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE
    Publication number: 20210052560
    Abstract: This invention provides a method of maintaining functional capacity, improving functional capacity, or lessening the decline of functional capacity in a human patient comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine such that a dose of 90 mg of pridopidine is administered to the patient per day, so as to thereby maintain functional capacity, improve functional capacity, or lessen the decline of functional capacity in the human patient.
    Type: Application
    Filed: September 13, 2020
    Publication date: February 25, 2021
    Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michael Hayden, Michal Geva
  • METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE
    Publication number: 20210030734
    Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine.
    Type: Application
    Filed: October 21, 2020
    Publication date: February 4, 2021
    Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michal GEVA, Michael Hayden
  • Selective Reduction of Allelic Variants
    Publication number: 20200377946
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).
    Type: Application
    Filed: January 14, 2020
    Publication date: December 3, 2020
    Applicants: Ionis Pharmaceuticals, Inc., The University of British Columbia
    Inventors: C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze
  • USE OF PRIDOPIDINE FOR THE TREATMENT OF ANXIETY AND DEPRESSION
    Publication number: 20200375966
    Abstract: The invention provides a method of reducing anxiety and/or depression in a subject comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to reduce anxiety and/or depression in a subject in the subject.
    Type: Application
    Filed: September 15, 2017
    Publication date: December 3, 2020
    Applicant: PRILENIA THERAPEUTICS DEVELOPMENT LTD
    Inventors: Michael HAYDEN, Mahmoud Abdulhossein POULADI
  • Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
    Patent number: 10828308
    Abstract: Methods of treating patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those also suffering from type II diabetes mellitus (T2DM), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: November 10, 2020
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Yaron Ilan, Doina Cosma Roman, Michael Hayden, Einat Amit-Romach
  • METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE
    Publication number: 20200179355
    Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine as monotherapy or together with riluzole, edaravone, combination of dextromethorphan/quinidine, sodium phenylbutyrate (PB), tauroursodeoxycholic acid or combination of sodium phenylbutyrate (PB)/tauroursodeoxycholic acid (i.e. AMX0035) as combination or add-on therapy.
    Type: Application
    Filed: February 13, 2020
    Publication date: June 11, 2020
    Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michal GEVA, Ralph LAUFER, Michael HAYDEN, Neta ZACH